These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 24424469)

  • 1. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
    Sanchez C; Reines EH; Montgomery SA
    Int Clin Psychopharmacol; 2014 Jul; 29(4):185-96. PubMed ID: 24424469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
    Mansari ME; Wiborg O; Mnie-Filali O; Benturquia N; Sánchez C; Haddjeri N
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):31-40. PubMed ID: 16448580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escitalopram.
    Aronson S; Delgado P
    Drugs Today (Barc); 2004 Feb; 40(2):121-31. PubMed ID: 15045034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.
    Mandrioli R; Mercolini L; Saracino MA; Raggi MA
    Curr Med Chem; 2012; 19(12):1846-63. PubMed ID: 22414078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
    Kennedy SH; Andersen HF; Lam RW
    J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Strawn JR; Mills JA; Croarkin PE
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
    [No Abstract]   [Full Text] [Related]  

  • 7. Escitalopram: a review of its use in the management of major depressive disorder in adults.
    Garnock-Jones KP; McCormack PL
    CNS Drugs; 2010 Sep; 24(9):769-96. PubMed ID: 20806989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypobaric hypoxia exposure in rats differentially alters antidepressant efficacy of the selective serotonin reuptake inhibitors fluoxetine, paroxetine, escitalopram and sertraline.
    Kanekar S; Sheth CS; Ombach HJ; Olson PR; Bogdanova OV; Petersen M; Renshaw CE; Sung YH; D'Anci KE; Renshaw PF
    Pharmacol Biochem Behav; 2018 Jul; 170():25-35. PubMed ID: 29738811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxetine: a review.
    Bourin M; Chue P; Guillon Y
    CNS Drug Rev; 2001; 7(1):25-47. PubMed ID: 11420571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escitalopram in the treatment of major depressive disorder: a meta-analysis.
    Kennedy SH; Andersen HF; Thase ME
    Curr Med Res Opin; 2009 Jan; 25(1):161-75. PubMed ID: 19210149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
    Shih YC; Bekele NB; Xu Y
    Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].
    Mnie-Filali O; El Mansari M; Scarna H; Zimmer L; Sánchez C; Haddjeri N
    Encephale; 2007 Dec; 33(6):965-72. PubMed ID: 18789789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Citalopram versus other anti-depressive agents for depression.
    Cipriani A; Purgato M; Furukawa TA; Trespidi C; Imperadore G; Signoretti A; Churchill R; Watanabe N; Barbui C
    Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD006534. PubMed ID: 22786497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Paroxetine (paxil): use in clinical practice].
    Litvintsev SV; Reznik AM; Arbuzov AL; Mironychev GN
    Voen Med Zh; 2002 Jan; 323(1):35-9. PubMed ID: 11881199
    [No Abstract]   [Full Text] [Related]  

  • 16. [Differential features of SSRIs].
    Cervera S
    Rev Med Univ Navarra; 1997; 41(4):245-57. PubMed ID: 10420965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxetine versus other anti-depressive agents for depression.
    Purgato M; Papola D; Gastaldon C; Trespidi C; Magni LR; Rizzo C; Furukawa TA; Watanabe N; Cipriani A; Barbui C
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD006531. PubMed ID: 24696195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.
    Zhong H; Haddjeri N; Sánchez C
    Psychopharmacology (Berl); 2012 Jan; 219(1):1-13. PubMed ID: 21901317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up.
    Peselow ED; Tobia G; Karamians R; Pizano D; IsHak WW
    Psychiatry Res; 2015 Feb; 225(3):680-6. PubMed ID: 25496869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.